- Home
- NYMT vs ERAS Comparison
NYMT vs ERAS Comparison
Compare NYMT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYMT
- ERAS
- Stock Information
- Founded
- NYMT 2003
- ERAS 2018
- Country
- NYMT United States
- ERAS United States
- Employees
- NYMT N/A
- ERAS N/A
- Industry
- NYMT Real Estate Investment Trusts
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- NYMT Real Estate
- ERAS Health Care
- Exchange
- NYMT Nasdaq
- ERAS Nasdaq
- Market Cap
- NYMT 538.5M
- ERAS 448.1M
- IPO Year
- NYMT 2004
- ERAS 2021
- Fundamental
- Price
- NYMT $6.46
- ERAS $1.41
- Analyst Decision
- NYMT Buy
- ERAS Strong Buy
- Analyst Count
- NYMT 5
- ERAS 5
- Target Price
- NYMT $7.13
- ERAS $5.70
- AVG Volume (30 Days)
- NYMT 638.2K
- ERAS 1.3M
- Earning Date
- NYMT 02-19-2025
- ERAS 03-26-2025
- Dividend Yield
- NYMT 12.38%
- ERAS N/A
- EPS Growth
- NYMT N/A
- ERAS N/A
- EPS
- NYMT N/A
- ERAS N/A
- Revenue
- NYMT $143,074,000.00
- ERAS N/A
- Revenue This Year
- NYMT N/A
- ERAS N/A
- Revenue Next Year
- NYMT $37.41
- ERAS N/A
- P/E Ratio
- NYMT N/A
- ERAS N/A
- Revenue Growth
- NYMT N/A
- ERAS N/A
- 52 Week Low
- NYMT $5.14
- ERAS $1.41
- 52 Week High
- NYMT $7.40
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- NYMT 64.90
- ERAS 25.44
- Support Level
- NYMT $5.63
- ERAS $1.52
- Resistance Level
- NYMT $6.17
- ERAS $1.76
- Average True Range (ATR)
- NYMT 0.18
- ERAS 0.13
- MACD
- NYMT 0.03
- ERAS 0.00
- Stochastic Oscillator
- NYMT 78.30
- ERAS 0.00
About NYMT New York Mortgage Trust Inc.
New York Mortgage Trust Inc is a real estate investment trust for federal income tax purposes, in the business of acquiring, investing in, financing and managing mortgage-related and residential housing-related assets. The company's investment portfolio consists of Structured multi-family property investments such as multi-family CMBS an preferred equity in, and mezzanine loans to owners of multi-family properties. Distressed residential assets such as residential mortgage loans sourced from distressed markets and non-Agency RMBS. Second mortgages, Agency RMBS, and certain other mortgage-related and residential housing-related assets.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.